Be the first to know about new programs and information with email alerts.
This year the meeting of the American Society of Hematology, or ASH, in Orlando, Florida, was very encouraging for people who are concerned about multiple myeloma. We wanted to get a wrap-up and find out what’s significant for patients. It’s all next on Patient Power.
Hello and welcome to Patient Power. I’m Andrew Schorr. This program is supported through a grant from Onyx Pharmaceuticals.
Well, I spent several days in Orlando, Florida, at the American Society of Hematology meeting, and there was a lot of news that was very encouraging for people who are concerned about myeloma. And whatever stage you are with the illness or if it’s a family member, there’s something to talk about, and we did on video with several experts, and that’s all at patientpower.info/ash, but also we wanted to gain the perspective of another expert who we’ve invited for this recording and also to have a little time to think about it. You know, when you step away from it where there are so many poster sessions and so much research it can be just dizzying, if you will. And fortunately the pace of myeloma research and the options available seem to go increasing, so that’s what we’ll be discussing, also answering some of the questions that have been sent in to Patient Power.
Helping me with all this is someone who has been living with myeloma for 16 years. Joining us from San Jose, California, is Jack Aiello. Jack, I know we got your perspective on video, but you’ve had a couple of weeks to think about it. Are you encouraged in what you’ve been saying to other patients around the country and around the world?
Yes. Thanks for inviting me, Andrew, on this call. I really enjoyed attending ASH, and when I talk with other patients, as I did this weekend through our support group, we’re all overwhelmed by again the number of newer treatments available, combination treatments, new drugs, discussions of maintenance, etc., so I’m looking forward to learning on this conference call as well as asking questions.